<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32437409</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot's acute neuroarthropathy.</ArticleTitle><Pagination><StartPage>e0233168</StartPage><MedlinePgn>e0233168</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0233168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0233168</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Aggressive antidiabetic therapy and rapid glycemic control are associated with diabetic neuropathy. Here we investigated if this is also the case for Charcot neuroarthropathy.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS">HbA1c levels and other relevant data were extracted from medical databases of 44 cases of acute Charcot neuroarthropathy.</AbstractText><AbstractText Label="RESULTS">HbA1c levels significantly declined from 8.25% (67mmol/mol) [7.1%-9.4%](54-79mmol/mol), at -6 months (M-6), to 7.40%(54mmol/mol) [6.70%-8.03%] (50-64 mmol/mol) during the six months preceding the diagnosis of Charcot neuroarthropathy (P &lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">HbA1c levels significantly declined during the six months preceding the onset of Charcot neuroarthropathy. This decline seems to be a associated factor with the appearance of an active phase of Charcot neuroarthropathy in poorly controlled patients with diabetic sensitive neuropathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dardari</LastName><ForeName>Dured</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7172-4300</Identifier><AffiliationInfo><Affiliation>Department of Diabetes, Sud Francilien Hospital Center, Corbeil-Essonnes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM UMRS 1138, Cordeliers Research Center, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van</LastName><ForeName>Georges Ha</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Diabetes, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M'Bemba</LastName><ForeName>Jocelyne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Podology Unit, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laborne</LastName><ForeName>Francois-Xavier</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Sud Francilien Hospital Center, Corbeil-Essonnes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourron</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>INSERM UMRS 1138, Cordeliers Research Center, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne University, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diabetes, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davaine</LastName><ForeName>Jean Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>INSERM UMRS 1138, Cordeliers Research Center, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Vascular Surgery Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM UMRS 1138, Cordeliers Research Center, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne University, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diabetes, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foufelle</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM UMRS 1138, Cordeliers Research Center, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaisser</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM UMRS 1138, Cordeliers Research Center, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penfornis</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Diabetes, Sud Francilien Hospital Center, Corbeil-Essonnes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris-Sud Medical School, Paris-Saclay University, Corbeil-Essonnes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartemann</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM UMRS 1138, Cordeliers Research Center, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne University, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diabetes, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003928" MajorTopicYN="Y">Diabetic Nephropathies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32437409</ArticleId><ArticleId IdType="pmc">PMC7241699</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0233168</ArticleId><ArticleId IdType="pii">PONE-D-20-06583</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gibbons CH, Treatment-induced neuropathy of diabetes. Curr Diab Rep 2017;17:127 10.1007/s11892-017-0960-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-017-0960-6</ArticleId><ArticleId IdType="pubmed">29064042</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons CH, Freeman R, Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015;138:43&#x2013;52. 10.1093/brain/awu307</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu307</ArticleId><ArticleId IdType="pmc">PMC4285188</ArticleId><ArticleId IdType="pubmed">25392197</ArticleId></ArticleIdList></Reference><Reference><Citation>Trieb K, The Charcot foot: pathophysiology, diagnosis and classification. Bone Joint J 2016;98-B:1155&#x2013;1159. 10.1302/0301-620X.98B9.37038</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.98B9.37038</ArticleId><ArticleId IdType="pubmed">27587513</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajbhandari SM, Jenkins RC, Davies C, et al., Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002;45:1085&#x2013;1096. 10.1007/s00125-002-0885-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-002-0885-7</ArticleId><ArticleId IdType="pubmed">12189438</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardari D, Penfornis A, Amadou C, et al., Multifocal (tarsus and knee) activation ofneuroarthropathy following rapid glycaemic correction. J Diabetes Complications 2019; Dec;33(12)</Citation><ArticleIdList><ArticleId IdType="pubmed">31668589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: The Charcot foot In: Frykberg RG (ed) The high risk foot in diabetes mellitus. Churchill Livingstone, New York, 1991. pp. 297&#x2013;338.</Citation></Reference><Reference><Citation>Frykberg RG. The high risk foot in diabetes mellitus. Churchill Livingstone, 1991. pp. 569&#x2013;572</Citation></Reference><Reference><Citation>Chantelau E, Grutzner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly 2014: w13948</Citation><ArticleIdList><ArticleId IdType="pubmed">24764120</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman BW, Using Kernel density estimates to investigate multimodality. J R Statist Soc B 1981;43:97&#x2013;99.</Citation></Reference><Reference><Citation>Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000;23:796&#x2013;800.27. 10.2337/diacare.23.6.796</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.23.6.796</ArticleId><ArticleId IdType="pubmed">10840999</ArticleId></ArticleIdList></Reference><Reference><Citation>Klenerman L. The Charcot neuroarthropathy joint in diabetes. Diabet Med. 1996;13:S52&#x2013;S54.</Citation><ArticleIdList><ArticleId IdType="pubmed">8741831</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot&#x2019;s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetlogia 2008;51(6):1035&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2362134</ArticleId><ArticleId IdType="pubmed">18389210</ArticleId></ArticleIdList></Reference><Reference><Citation>Folestad A, &#xc5;lund M, Asteberg S, Fowelin J, Aurell Y, G&#xf6;thlin J, et al. Role of Wnt/&#x3b2;-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Acta Orthop. 2015;86(4):415&#x2013;25. 10.3109/17453674.2015.1033606</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17453674.2015.1033606</ArticleId><ArticleId IdType="pmc">PMC4513595</ArticleId><ArticleId IdType="pubmed">25811776</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang GD, Sun HL, Zhao LS, Hou J, Yue L, Xu L.Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients Zhonghua Yi Xue Za Zhi. 2007. May 15;87(18):1234&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17686254</ArticleId></ArticleIdList></Reference><Reference><Citation>Murchison R, Gooday C, Dhatariya K, The development of a charcot foot after significant weight loss in people with diabetes: three cautionary tales. J Am Podiatr Med Assoc 2014;104:522&#x2013;525. 10.7547/0003-0538-104.5.522</Citation><ArticleIdList><ArticleId IdType="doi">10.7547/0003-0538-104.5.522</ArticleId><ArticleId IdType="pubmed">25275743</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia Barrado F, Kuypers DR, Matricali GA, Charcot neuroarthropathy after simultaneous pancreas-kidney transplantation: risk factors, prevalence, and outcome. Clin Transplant 2015;29:712&#x2013;719. 10.1111/ctr.12572</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.12572</ArticleId><ArticleId IdType="pubmed">26033225</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe4;mann A, Pofahl S, Lehmann T, Voigt B, Victor S, M&#xf6;ller F, et al. Diabetic nephropathy but not HbA1c is predictive for frequent complications of Charcot feet&#x2014;long-term follow-up of 164 consecutive patients with 195 acute Charcot feet. Exp Clin Endocrinol Diabetes. 2012. June;120(6):335&#x2013;9. Epub 2012 Mar 15.</Citation><ArticleIdList><ArticleId IdType="pubmed">22421981</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffcoate W.J. Theories concerning the pathogenesis of the acute Charcot foot suggest future therapy Curr Diab Rep, 5 (2005), pp. 430&#x2013;435 10.1007/s11892-005-0050-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-005-0050-z</ArticleId><ArticleId IdType="pubmed">16316593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>